RETaliation-tackling rare resistance alterations to osimertinib
Krebs, Matthew G Popat, S.
Krebs, Matthew G
Popat, S.
Citations
Altmetric:
Abstract
RET fusions occur as a rare mechanism of acquired resistance to osimertinib in patients with EGFR mutation-positive non-small cell lung cancer. Inhibiting RET alongside osimertinib shows promising clinical activity, but innovative approaches are needed to seek regulatory approvals in these rare treatment resistance settings.
Authors
Description
Date
2023
Publisher
Collections
Keywords
Type
Article
Citation
Krebs MG, Popat S. RETaliation-Tackling Rare Resistance Alterations to Osimertinib. Clinical Cancer Research. 2023 Aug;29(16):2951-3. PubMed PMID: WOS:001052467500001.